Cooperative Agreement UG3CA290454
Award Date
7/9/25
Completion Date
6/30/27
Dollars Obligated
$597K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award, valued at $407,321 and awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), supports research to investigate alternative splicing and isoform expression as mediators of the genetic etiology of breast cancer. The key objectives are to: Quantify isoform expression and alternative splicing events in breast tissue using novel transcript assemblies from long-read RNA sequencing data. This will involve benchmarking statistical...
The National Cancer Institute (NCI) awarded a $734,785 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Vanderbilt University Medical Center. The 5-year grant, effective September 1, 2024, will fund a proteogenomics study to identify proteins associated with breast cancer risk. The study will integrate genomics and proteomics data from over 5,000 normal breast tissue samples and 125 breast cancer tissue samples to discover putative target proteins for...
The University of Texas MD Anderson Cancer Center received a $729,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing novel strategies for immunoprevention of estrogen receptor-negative breast cancer. The three-year award, issued on December 31, 2021 with a completion date of December 30, 2024, will fund applied and advanced biomedical research...
This $2,556,071 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas Health Science Center at San Antonio. The award supports a collaborative research program focused on elucidating the mechanisms by which the BRCA1-BARD1 and BRCA2 tumor suppressors promote homologous recombination (HR) DNA repair, and how this is negatively regulated by the 53BP1 axis to favor the use of...
This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to develop and evaluate antibody-drug conjugates (ADCs) that target the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) Generate GPR56-targeted ADCs by attaching various cytotoxic drugs and assess their cell-killing potency in TNBC cell lines; 2) Evaluate the...
This federal Project Grant award, totaling $244,228.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will fund a research project led by the University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping patient tumor samples to preclinical lung cancer models. The key objectives are to: 1) expand proteomic profiling of lung cancer patient-derived xenograft...
This $670,358 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate the role of B cell lineages in mediating response to neoadjuvant immune-based therapy for resectable non-small cell lung cancer (NSCLC). The research will leverage unique clinical trial cohorts, human-relevant mouse models, and advanced multi-omics technologies to determine the transcriptional, immunogenomic, and spatial landscapes of B lineage cells in NSCLC...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584.00 to The University of Texas MD Anderson Cancer Center to conduct research on the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The overarching goal is to expand the fundamental understanding of MTNBC metastasis by investigating the genomic and transcriptomic evolution of primary tumor cells and their...